{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:16:29Z","timestamp":1792696589350,"version":"4.5.0"},"reference-count":53,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T00:00:00Z","timestamp":1425513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ketoconazole was the first broad-spectrum oral antifungal agent available to treat systemic and superficial mycoses. Evidence of hepatotoxicity associated with its use emerged within the first few years of its approval. Growing evidence of serious side effects including endocrine dysregulation, several drug interactions, and death led to the review of oral ketoconazole in 2011.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This article chronicles the use of oral ketoconazole from its introduction to its near replacement in medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Due to its hepatotoxic side effects, oral ketoconazole was withdrawn from the European and Australian markets in 2013. The United States imposed strict relabeling requirements and restrictions for prescription, with Canada issuing a risk communication echoing these concerns. Today, oral ketoconazole is only indicated for endemic mycoses, where alternatives are not available or feasible. Meanwhile, topical ketoconazole is effective, safe, and widely prescribed for superficial mycoses, particularly as the first-line treatment for tinea versicolor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1203475415574970","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T17:54:37Z","timestamp":1426010077000},"page":"352-357","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":97,"title":["The Rise and Fall of Oral Ketoconazole"],"prefix":"10.1177","volume":"19","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Canada"},{"name":"Mediprobe Research Inc., London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika C.A.","family":"Lyons","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc., London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"bibr1-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)81495-8"},{"key":"bibr2-1203475415574970","unstructured":"Food and Drug Administration. Label and approval history. http:\/\/www.accessdata.fda.gov\/Scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed February 12, 2015."},{"key":"bibr3-1203475415574970","first-page":"1","volume":"10","author":"Maertens JA","year":"2004","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"bibr4-1203475415574970","first-page":"1","author":"European Medicines Agency","year":"2013","journal-title":"Eur Med Agency"},{"key":"bibr5-1203475415574970","unstructured":"Administration AGD of HTG. Oral ketoconazole (Nizoral) 200 mg tablets. http:\/\/www.tga.gov.au\/safety\/alerts-medicine-oral-ketoconazole-131010.htm#.U0gmjfldWCk. Accessed April 11, 2014."},{"key":"bibr6-1203475415574970","first-page":"1","author":"Gupta AK","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"bibr7-1203475415574970","unstructured":"Health Canada. Health Canada endorsed important safety information on ketoconazole. http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2013\/34173a-eng.php. Published 2013. Accessed May 30, 2014."},{"key":"bibr8-1203475415574970","unstructured":"Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm362415.htm. Published July 26, 2013. Accessed February 12, 2015."},{"key":"bibr9-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/2.4.625"},{"key":"bibr10-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.1.2.187"},{"key":"bibr11-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1378\/chest.54.Supplement_1.296"},{"key":"bibr12-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)72045-0"},{"key":"bibr13-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/138.2.245"},{"key":"bibr14-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.6.922"},{"key":"bibr15-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1979.tb01757.x"},{"key":"bibr16-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/6.1.97"},{"key":"bibr17-1203475415574970","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-6-921"},{"key":"bibr18-1203475415574970","unstructured":"Drugs@FDA: FDA approved drug products. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory. Accessed April 28, 2014."},{"key":"bibr19-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1021\/jm00194a023"},{"key":"bibr20-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1007\/BF01960348"},{"key":"bibr21-1203475415574970","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198223010-00001"},{"key":"bibr22-1203475415574970","unstructured":"Janssen Pharmaceutica NV. Business information, profile, and history. http:\/\/companies.jrank.org\/pages\/2250\/Janssen-Pharmaceutica-N-V.html. Accessed May 26, 2014."},{"key":"bibr23-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90519-3"},{"key":"bibr24-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.6.1073"},{"key":"bibr25-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.12.1874"},{"key":"bibr26-1203475415574970","volume":"312","author":"Craven PC","year":"1985","journal-title":"N Engl J Med"},{"key":"bibr27-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91517-X"},{"key":"bibr28-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.400"},{"key":"bibr29-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(84)80021-9"},{"key":"bibr30-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80495-0"},{"key":"bibr31-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00095.x"},{"key":"bibr32-1203475415574970","unstructured":"Johnson & Johnson unit agrees to stiffen nizoral label warnings. Wall Street Journal. http:\/\/search.proquest.com.proxy1.lib.uwo.ca\/docview\/134874933\/abstract\/E1F9C9D5D6D14CB7PQ\/5?accountid=15115. Accessed May 21, 2014."},{"key":"bibr33-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250119"},{"key":"bibr34-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.294.6569.419"},{"key":"bibr35-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260341"},{"key":"bibr36-1203475415574970","first-page":"605","volume":"26","author":"Yan JY","year":"2013","journal-title":"Biomed Environ Sci BES"},{"key":"bibr37-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90515-6"},{"key":"bibr38-1203475415574970","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-97-3-370"},{"key":"bibr39-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-5-1193"},{"key":"bibr40-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-4-732"},{"key":"bibr41-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110903"},{"key":"bibr42-1203475415574970","first-page":"47","volume":"2","author":"Boxenbaum H","year":"1999","journal-title":"J Pharm Pharm Sci Publ Can Soc Pharm Sci Soci\u00e9t\u00e9 Can Sci Pharm"},{"key":"bibr43-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.a101207"},{"key":"bibr44-1203475415574970","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814010-00002"},{"key":"bibr45-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1671"},{"key":"bibr46-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.2.319"},{"key":"bibr47-1203475415574970","first-page":"35","volume":"3","author":"Ford N","year":"2011","journal-title":"HIVAIDS Auckl NZ"},{"key":"bibr48-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.67"},{"key":"bibr49-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20132463"},{"key":"bibr50-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2012.01.003"},{"key":"bibr51-1203475415574970","unstructured":"Janssen Pharmaceutica. Nizoral (ketoconazole) 2% shampoo. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019927s032lbl.pdf. Accessed November 11, 2014."},{"key":"bibr52-1203475415574970","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.931373"},{"key":"bibr53-1203475415574970","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1825"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475415574970","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475415574970","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475415574970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:53:10Z","timestamp":1777391590000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475415574970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,5]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1177\/1203475415574970"],"URL":"https:\/\/doi.org\/10.1177\/1203475415574970","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,5]]}}}